Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
2.150
0.00 (0.00%)
At close: Sep 17, 2025, 4:00 PM EDT
2.230
+0.080 (3.72%)
After-hours: Sep 17, 2025, 5:10 PM EDT
Celularity Revenue
Celularity had revenue of $5.74M in the quarter ending June 30, 2025, a decrease of -52.64%. This brings the company's revenue in the last twelve months to $44.59M, up 4.45% year-over-year. In the year 2024, Celularity had annual revenue of $54.22M with 138.11% growth.
Revenue (ttm)
$44.59M
Revenue Growth
+4.45%
P/S Ratio
1.11
Revenue / Employee
$362,520
Employees
123
Market Cap
57.39M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.22M | 31.45M | 138.11% |
Dec 31, 2023 | 22.77M | 4.80M | 26.68% |
Dec 31, 2022 | 17.98M | -3.36M | -15.75% |
Dec 31, 2021 | 21.34M | 7.06M | 49.43% |
Dec 31, 2020 | 14.28M | -6.87M | -32.48% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CELU News
- 14 days ago - Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance - GlobeNewsWire
- 26 days ago - Celularity Receives Nasdaq Notice Regarding Form 10-Q - GlobeNewsWire
- 4 weeks ago - Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt - GlobeNewsWire
- 2 months ago - Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law - GlobeNewsWire
- 2 months ago - Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies - GlobeNewsWire
- 3 months ago - Celularity Announces Chief Financial Officer Transition - GlobeNewsWire
- 3 months ago - Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology - GlobeNewsWire
- 4 months ago - Celularity Announces Full Year 2024 Operating and Financial Results - GlobeNewsWire